Severe combined immunodeficiency (SCID) patients with an inactivating mutation in recombination activation gene 1 (RAG1) lack B and T cells due to the inability to rearrange immunoglobulin (Ig) and T-cell receptor (TCR) genes. Gene therapy is a valid treatment option for RAG-SCID patients, especially for patients lacking a suitable bone marrow donor, but developing such therapy has proven challenging. As a preclinical model for RAG-SCID, we used Rag1À/À mice and lentiviral self-inactivating (SIN) vectors harboring different internal elements to deliver native or codon-optimized human RAG1 sequences. Treatment resulted in the appearance of B and T cells in peripheral blood and developing B and T cells were detected in central lymphoid organs. Serum Ig levels and Ig and TCR Vb gene segment usage was comparable to wildtype (WT) controls, indicating that RAG-mediated rearrangement took place. Remarkably, relatively low frequencies of B cells produced WT levels of serum immunoglobulins. Upon stimulation of the TCR, corrected spleen cells proliferated and produced cytokines. In vivo challenge resulted in production of antigen-specific antibodies. No leukemia development as consequence of insertional mutagenesis was observed. The functional reconstitution of the B-as well as the T-cell compartment provides proof-of-principle for therapeutic RAG1 gene transfer in Rag1À/À mice using lentiviral SIN vectors.
Introduction
Severe combined immunodeficiency (SCID) comprises a group of rare diseases in which lymphocytes are unable to develop or function normally. The phenotype of SCID depends on the underlying genetic defect, but all SCID patients lack autologous T lymphocytes in their peripheral blood. [1] [2] [3] [4] [5] SCID patients with a mutation in the recombination activation gene 1 or 2 (RAG1 or RAG2) lack both T and B lymphocytes because RAG proteins are crucial for the rearrangement of immunoglobulin (Ig) and T-cell receptor (TCR) genes. In the absence of these rearrangements, functional Ig and TCR chains will not be produced by B-and T-cell progenitors in bone marrow (BM) and thymus. This leads to a developmental arrest causing the T-B-SCID phenotype. [6] [7] [8] [9] Allogeneic hematopoietic stem cell transplantation is a curative treatment for SCID, with the 3-year survival of a human leukocyte antigen-identical transplantation being significantly better than a, more widely available, mismatched transplantation. 10 However, an human leukocyte antigenidentical donor is often not available, so SCID patients mostly have to rely on mismatched donors. Over the past decades, gene therapy utilizing long terminal repeat (LTR)-driven g-retrovirusbased vectors has emerged as an alternative treatment option for SCID. Several clinical trials have been successful in the treatment of adenosine deaminase-SCID and X-linked SCID patients. [11] [12] [13] In addition, therapeutic LTR-driven g-retroviral transfer vectors have been developed and tested for other SCID-causing genetic aberrations, such as Artemis, IL7RA, RAG1 and RAG2. [14] [15] [16] [17] Unfortunately, clonal T-cell proliferations were observed in 4 out of 10 patients enrolled in the French X-linked SCID gene therapy trial 18, 19 and in 1 out of 10 patients in the British X-linked SCID trial. The occurrence of clonal T-cell proliferations has lead to widespread efforts to improve the safety of gene transfer methods. Using a different vector system is one of the options to improve safety (reviewed in Staal et al. 20 ). Over the past 15 years, lentiviral transfer systems underwent several rounds of modifications to improve their safety. [21] [22] [23] [24] An additional modification resulted in the lentiviral self-inactivating (SIN) vector system. SIN vectors, both g-retroviral and lentiviral, contain a LTR from which viral promoter-enhancer sequences have been deleted from the U3 region of the 3 0 LTR, leaving the LTR transcriptionally inactive when integrated into the host genome. 22, 25, 26 In vitro studies have shown that, compared with g-retroviral vectors, lentiviral vectors have a more favorable integration pattern. 27 Integrations of lentiviral vectors are spread out over the transcriptional part of genes, whereas g-retroviral vectors tend to integrate more near DNAse I-hypersensitive sites 28 and toward the transcription start site of genes, 27 regions that mostly contain regulatory elements. Some studies have already shown partial or full phenotypic correction of primary immunodeficiencies using lentiviral SIN vectors 29, 30 indicating that these vectors are a good option for the use in human RAG1 gene transfer.
Studying the efficacy of human RAG1-containing transfer vectors is facilitated by the availability of a murine model that is equivalent to the situation in RAG-SCID patients; 31 In Rag1À/À mice, the development of B cells is blocked at an early B220 low IgMÀ pro-B cell stage and T-cell development cannot progress beyond b selection in the CD4ÀCD8À double negative stage. In the current study, several lentiviral SIN transfer vectors were constructed in which expression of the native human RAG1 cDNA sequence or a codon-optimized version of human RAG1 cDNA is driven by the human elongation factor 1a (EFS) promoter, 32 the enhancer-promoter of the spleen-focus-forming virus (SFFV) or a ubiquitously acting chromatin opening element from the human HNRPA2B1-CBX3 locus (A2UCOE). 33 In addition, the transfer vectors contain a truncated version of the woodchuck hepatitis virus-derived post-transcriptional regulatory element (WPRE), which augments both viral titer and transgene expression. 34, 35 All vectors were devoid of GFP or other tags, in that respect making them suitable for clinical application. Hematopoietic precursor cells from murine Rag1À/À BM were subjected to ex vivo gene transfer using the constructed lentiviral SIN vectors and transplanted into lethally irradiated Rag1À/À recipient mice. We evaluated reconstitution of central and peripheral lymphoid compartments, in vitro and in vivo lymphocyte function, as well as the Ig and TCR repertoire.
Materials and methods

Mice
C57BL/6Rag1À/À mice were obtained from The Jackson Laboratory (Bar Harbor, ME, USA). C57BL/6 wild-type (WT) mice were purchased from Charles River Nederland (Maastricht, the Netherlands). Mice were maintained in the specified pathogen-free breeding section of the Experimental Animal Center of the Erasmus MC, University Medical Center, Rotterdam, the Netherlands. This study was approved by the institutional Animal Ethical Committee of the Erasmus MC, Rotterdam, the Netherlands.
Lentiviral vectors
Lentiviral gene transfer constructs were derived from pRRL.PPT.PGK.GFPpre. 22 The pRRL.PPT.EFS.RAG1.pre (hereafter EFS.RAG1), pRRL.PPT.SFFV.RAG1.pre (hereafter SFFV.RAG1), pRRL.PPT.EFS.coRAG1.pre (hereafter EFS.coRAG1), pRRL.PPT. SFFV.coRAG1.pre (hereafter SFFV.coRAG1) and pRRL.PPT. UCOE.coRAG1.pre (hereafter UCOE.coRAG1) transfer vectors were constructed as described in Supplementary Materials and Methods.
Transduction and transplantation of BM cells
Lineage-negative cells, selected using magnetic beads, or sorted Lineage À Sca-1 þ c-Kit þ (LSK) cells (490% purity) were grown in StemSpan-SFEM (Stemcell Technologies Inc., Vancouver, BC, Canada) supplemented with 100 ng/ml recombinant mouse stem cell factor (rmSCF), 10 ng/ml recombinant mouse thrombopoietin (rmTPO) and 50 ng/ml recombinant mouse fms-related tyrosine kinase 3 ligand (rhFLT3-L) (all Stemcell Technologies Inc.) for 1 day. Rag1À/À cells were subsequently transduced by way of spin occulation in the presence of 4 mg/ml protamine sulfate (Sigma-Aldrich, St Louis, MO, USA) at 800 g and 32 1C for 1 h. Cells were transduced using 1500-2000 WPRE copies/ cell (approximate multiplicity of infection of [23] [24] [25] [26] [27] [28] [29] [30] 
Real-time quantitative PCRs
Real-time quantitative PCRs (RQ-PCRs) were used for the quantitative analysis of genomic lentiviral RNA, proviral DNA copies and transgene mRNA expression using WPRE, RAG1, coRAG1 and Abelson (ABL) as targets. Details are described in Supplementary Materials and Methods.
Flow cytometric studies and cell sorting 
Ig and TCRb repertoire analysis
Total RNA was extracted from spleen cells using the RNeasy Total RNA isolation kit (Qiagen, Hilden, Germany) and reverse transcribed into cDNA. For TCRb repertoire analysis, a method from Pannetier et al. 36 was modified into a single-step PCR. Briefly, cDNA was amplified using a 6-carboxyfluorescein (FAM)-labeled C gene segment-specific primer (5 0 -FAM-CTTGGGTGGAGTCACATTTCTC-3 0 ) 36 along with 22 murine TCR Vb-specific primers. 36 For immuno globulin heavychain repertoire analysis, primers were designed according to the guidelines of the BIOMED-2/EuroClonalty procedures for the 
Serum Ig quantification and immunization
Enzyme-linked immunosorbent assays (ELISAs) were used to determine IgM, IgG1 or IgG serum levels. To determine the T-cell-dependent immune response, mice were immunized by intraperitoneal injection of 100 mg TNP-KLH (Bioresearch Tec Inc., Novato, CA, USA) in 50% Imject Alum (Thermo Scientific, Rockford, IL, USA). Three weeks after the first injection, animals were given an intraperitoneal injection of 100 mg TNP-KLH in phosphate-buffered saline. Seven days after the second injection, serum was collected and TNP-specific IgG antibodies were determined. Serum taken before immunization was used as a baseline value.
In vitro proliferation and cytokine production assays
To determine the in vitro proliferative capacity of T cells in response to specific stimuli, spleen cells were labeled with 0.05 mM carboxy-fluorescein-succinimidyl ester (Molecular Probes, Carlsbad, CA, USA) and resuspended in IMDM medium containing 10% heat-inactivated fetal calf serum, penicillinstreptomycin (100 U/ml to 100 mg/ml), 0.5 M b-mercaptoethanol and 4 mM glutamine. In all, 2 Â 10 6 labeled spleen cells were cultured in plates that were pre-coated with 10 mg/ml aCD3 (145-2C11) (Bioceros, Utrecht, the Netherlands) and 10 mg/ml aCD28 (37.51) (BD Biosciences, Santa Clara, CA, USA). For intracellular detection of IL2 and IFNg, aCD3/aCD28-stimulated cells were cultured in the presence of GolgiStop (BD Pharmingen) for 4 h. Cells were stained extracellularly using R-phycoerythrin(PE)-conjugated CD4 (L3T4) and peridinin chlorophyll protein (PerCP)-conjugated CD8a (53-6.7), followed by fixation using paraformaldehyde, permeabilization using saponin and intracellular staining using allophycocyanin (APC)-conjugated IFNg (XMG1.2) or IL2 (JES6-5H4) antibodies (all antibodies from BD Biosciences). Data were acquired on a FACSCanto II (BD Biosciences).
Results
Improved transgene expression using codon-optimized RAG1 coding sequences
In initial tests for efficacy of gene therapy vectors for RAG1-SCID it was challenging to reach sufficient levels of RAG1 gene expression. In the first in vivo experiments, using various different promoters at vector copy numbers (VCNs) of B1, RAG1 gene expression levels were too low for full correction of the effects of RAG1 deficiency, as the block in T-cell development in the thymus was not alleviated (see Supplementary Figure 1 ). An independent set of experiments also yielded unsatisfactory results; 2 months after transplanting Sca-1 þ BM Rag1À/À progenitors transduced with an SIN lentiviral vector, in which RAG1 expression was driven by the EF-1a promoter, low numbers of peripheral T cells and a low frequency of double positive cells in the thymus were found in 5 out of 30 treated mice (Supplementary Table 1 ; Supplementary Figure 2) . Reconstitution of the B-cell compartment was not observed (Supplementary Figure 2) . In T-cell-reconstituted mice, high VCNs were detected in central and peripheral lymphoid organs. From a safety point of view, using a higher number of viral particles per cell is undesirable, as more proviral integrations would increase the chance of potential oncogene activation or disruption of tumor suppressor genes, so we explored an alternative way to enhance expression.
RAG proteins mediate DNA nicking and hairpin formation using chemistry that is identical to the DDE (asp-asp-gln) class of transposases, strongly suggesting that these genes originated outside the mammalian genome. 38 The differential frequency of tRNAs between the host species and the original species is the main cause of reduced translation efficiency. 39 Consequently, the codon usage is likely to be suboptimal for translation in mammalian cells. Analysis of the human RAG1 cDNA sequence (GeneArt, Regensburg, Germany) revealed several possibilities to improve the DNA sequence without affecting the amino-acid sequence, as many rare codons are present in the native RAG1 gene. Most of these codons were replaced by more frequently used codons of Homo sapiens genes. GC content was increased to augment mRNA stability. Finally, 21 cis-acting motifs (prokaryotic inhibitory motifs, splice donor sites, polyA sites and RNA instability motifs) that could negatively influence Table 1 Comparison of native and codon-optimized RAG1 with respect to B-and T-cell reconstitution, VCN and RAG1 expression, 19 weeks after transplantation
Donor cells Mice with B-cell reconstitution
Mice with T-cell reconstitution 
Preclinical lentiviral Rag1 gene therapy K Pike-Overzet et al expression were removed. No alterations were made to the amino-acid sequence, allowing regulatory mechanisms that occur at the protein level to function normally. Compared with the viral construct carrying the native RAG1 sequence, coRAG1 constructs yielded 2-to 3.5-fold higher viral titers (Figure 1a) . We tested the efficiency of RAG1 expression per vector copy, by transducing Rag1À/À BM cells, enriched for lineage-negative cells with viruses carrying native RAG1 or coRAG1. Six days after transduction, expression levels of the therapeutic vectors were determined by RQ-PCR on cDNA. The Preclinical lentiviral Rag1 gene therapy K Pike-Overzet et al VCN was determined on DNA by RQ-PCR through detection of the WPRE (Figure 1b) . Per vector copy, coRAG1 expression was B10-fold higher than native RAG1 for both the EFS and the SFFV promoter. To test the effect of codon optimization in vivo, transduced Rag1À/À lineage-negative enriched BM cells were injected into lethally irradiated Rag1À/À mice 1 day after transduction. Nineteen weeks after transplantation, we determined VCN and RAG1 or coRAG1 expression levels in spleen cells. We found that for the EFS-driven constructs, coRAG1 was expressed 5.66-fold higher than native RAG1 and for the SFFVdriven constructs, coRAG1 expression was 3.40-fold higher than RAG1 (Figure 1c ). More importantly, on a per-copy basis the EFS.coRAG1 resulted in transgene expression levels that were 8.53-fold higher than for EFS.RAG1. For SFFV.coRAG1, the transgene expression per vector copy was 37.80 times higher than for SFFV.RAG1 (Figure 1d ). In peripheral blood of the transplanted animals, the emergence of B and T cells was monitored by fluorescence-activated cell sorting analysis (Figures 1e and f) . Five weeks after transplantation, animals with B220 þ /IgM þ cells could be found in all test groups. Most B-cell-positive mice in the gene therapy groups showed only moderate B-cell reconstitution at this point, except SFFV.coR-AG1-treated mice, in which the percentage of B cells was substantial. Eight weeks after transplantation, only mice that received WT cells or SFFV.coRAG1 transduced cells showed peripheral blood T-cell reconstitution. Fluorescence-activated cell sorting analysis of spleen and peripheral blood 19 weeks after transplantation revealed that B-and T-cell reconstitution was not sustained in most treated mice, except for SFFV.coR-AG1-treated mice (Table 1) . With respect to the frequency of B-cell-reconstituted mice, for both EFS-and SFFV-driven constructs, coRAG1-treated mice performed better than the native RAG1-treated mice. The same holds true for the T-cell compartment in SFFV.coRAG1-treated mice versus SFFV.RAG1 -treated mice. Notably, the improved results for T-and B-cell reconstitution was reached with lower VCNs in coRAG1-treated mice (Table 1) . Moreover, the lower VCNs still resulted in higher RAG1 expression levels, demonstrating the beneficial effect of RAG1 coding sequence optimization.
# of cells in bone marrow
Correction of the Rag1À/À phenotype in primary lymphoid organs
We repeated the in vivo reconstitution experiment with EFS.coRAG1 and SFFV.coRAG1 to follow the mice over a period of 6 months. Primary lymphoid organs were analyzed for the presence of developing lymphocytes. Numbers of treated mice and the treatment success rate can be found in Supplementary Tables 2 and 3 . In the WT and SFFV.coRAG1-treated groups, developing B cells could be detected in the BM, including cells co-expressing IgM and IgD, indicating that rearrangement of Ig gene segments took place (Figure 2a) . We found very low coRAG1 expression in the BM of EFS.coRAG1-treated animals (data not shown), which could explain the lack of B-cell precursors. We determined the number of immature and mature B cells in the BM, combining total BM cell counts with the relative size of the populations as determined by flow cytometry (Figure 2b ). The average number of immature B cells found in SFFV.coRAG1-treated mice was about 40% of immature B cells found in WT mice. The number of mature B cells found in SFFV.coRAG1 mice was about 15% of the numbers found in WT animals. Developing B cells were low to absent in EFS.coRAG1-treated mice, despite relatively high VCNs (B10 in BM samples), which makes clinical application difficult. For animals treated with EFS.coRAG1 (Figure 2c ), UCOE.coRAG1 (Figure 2e ) and SFFV.coRAG1 (Figures 2c and e) all stages of T-cell development in the thymus could be detected (Figures 2c and e) . The number of double positive cells was rather low in SFFV.coRAG1-treated mice but EFS.coRAG1-as well as UCOE.coRAG1-treated animals showed comparable numbers to the WT group (Figures 2d and f) . Interestingly, the favorable results for UCOE.coRAG1 were obtained at low VCNs: 0.61 in spleen and 0.49 in BM. Thus, in these experiments, 5-6 months after transplantation, EFS.coRAG1-and UCOE.coRAG1-treated mice had significant numbers of developing B and T cells, with the VCNs in UCOE.coRAG1-treated mice being in a range that would be applicable in a clinical setting.
Presence of RAG recombinase activity
To determine whether rearrangement of Ig and TCR gene segments had taken place, total RNA extracted from spleen cells was used to analyze Ig and TCR Vb gene segment usage. In cDNA isolated from WT as well as treated animals, rearranged gene segments were detected when using the C m as well as the C g -specific primer, indicating functional RAG1 activity ( Figures  3a and b) . As expected, no immuno globulin heavychain rearrangements were detectable in Rag1À/À mice (data not shown). TCR Vb repertoire was determined on cDNA material by PCR using a fluorochrome-labeled constant b (Cb) gene segment-specific primer and 22 Vb-specific primers. 36 WT animals demonstrated a diverse TCR repertoire, as the whole spectrum of Vb gene segments tested showed in-frame rearrangements (Figure 3c ). Similar to immuno globulin heavychain, no rearranged Vb gene segments could be detected in Rag1À/À samples (data not shown). Material isolated from UCOE.coRAG-treated mice showed clear evidence of RAG recombinase activity as 16 out of 22 Vb segments underwent Ig rearrangements. Material derived from an SFFV.coRAG1-treated animal displayed in-frame rearrangements of most of the Vb gene segments analyses, and peak distribution was comparable to WT. In conclusion, detection of rearrangements of Ig as well as TCR gene segments shows that delivery of the coRAG1 transgene using an SIN lentiviral vector results in proper function of the RAG1/Rag2 recombinase complex.
Correction of the Rag1À/À phenotype in peripheral lymphoid organs
In an effort to further optimize the results of RAG1 gene transfer into hematopoietic progenitors, we isolated LSK hematopoietic progenitor cells, which were used as the target population for transduction using SFFV.coRAG1 and UCOE.coRAG1 viral vectors. After transplantation, peripheral blood cell samples were periodically monitored for the frequency of B and T cells by flow cytometry. Numbers of treated mice and the treatment success rate can be found in Supplementary Table 3 . The percentage of B cells in treated mice did not increase dramatically (Figure 4a ), but a clear B220 þ IgM þ population could be observed (Figure 4c ), confirming RAG recombinase activity. As shown in Figure 4b , T-cell reconstitution in gene therapy animals was robust, with SFFV.coRAG1-treated mice reaching nearly the same level of reconstitution as mice receiving WT cells and UCOE.coRAG1-treated mice reaching about 40% of WT levels. In mice transplanted with WT cells, we found a CD4/CD8 ratio of a little less than 2. For animals receiving SFFV.coRAG1-transduced cells the ratio was 1.4 and for UCOE.coRAG1-treated mice a ratio of 1.5 was found. We determined the number of B cells in peripheral blood and spleen (Figures 4e and f) . In both compartments, the number of B cells was low in UCOE.coRAG1-treated mice, but in SFFV.coRAG1-treated mice about 1/3 (peripheral blood) or 1/6 (spleen) of WT numbers were reached. In treated mice, peripheral blood T-cell numbers were comparable to animals receiving WT cells, while in spleen the number of T cells was about 1/3 of WT.
Although B-cell numbers were low in some cases, correction of the Rag1À/À phenotype was achieved with both viral vectors that we tested. 
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In vitro T-cell function
To test whether T cells generated in gene therapy-treated mice were functional, we assayed for proliferative capacity and the ability to produce cytokines in vitro. Peripheral blood samples from WT, Rag1À/À and SFFV.coRAG1-treated mice were carboxy-fluorescein-succinimidyl ester labeled and stimulated by plate-bound aCD3/aCD28 for 3 days. Cultured, unstimulated cells served as negative control. The ratio of proliferated CD4 þ cells over carboxy-fluorescein-succinimidyl ester-retaining CD4 þ cells was determined for unstimulated and stimulated cells (Figure 5a ). When stimulated, SFFV.coRAG1 CD4 þ cells were capable of proliferating at a higher rate than the background rate seen in Rag1À/À cells (P ¼ 0.0846, two-tailed, unpaired t-test). The percentage of intracellular IL2 þ cells under unstimulated conditions was comparable to SFFV. coRAG1 CD4 þ and WT CD4 þ cells and both test groups showed an increase in IL2 þ cells after stimulation (Figure 5b ). CD4 þ cells in WT and SFFV.coRAG1 samples also showed a significant increase in IFNg þ cells after stimulation (Figure 5c ). In addition, IFNg production in CD8 þ cells was also determined (Figure 5d ). In this case, the increase in the percentage of IFNg þ cells after stimulation was slightly lower in cells taken from SFFV.coRAG1-treated mice when compared with WT cells, but the cells were able to respond to the aCD3/ aCD28 stimulus. From these in vitro tests, we conclude that T cells generated in gene therapy-treated mice are capable of responding to TCR stimulation.
In vivo B-and T-cell function
To determine whether B cells that were detected in gene therapy animals were secreting Igs, their serum Ig levels (IgM and IgG) Peripheral Blood, week 20 
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were assessed by sandwich-ELISA (Figure 6a ). Sera of Rag1À/À did not have any detectable levels of IgM or IgG. In UCOE. coRAG1-and SFFV.coRAG1-treated animals, IgM and IgG concentrations were comparable to those found in WT animals. This illustrates that fairly low numbers of B cells in peripheral blood do not necessarily result in reduced serum Ig levels. To assess the T-cell-dependent immune response of B cells, we challenged the mice with intraperitoneal injections of TNP-KLH. After two rounds of immunization, the level of TNP-specific IgG antibodies was determined by ELISA (Figure 6b ). In animals that received Rag1À/À cells, TNP-specific antibodies were not detected. Mice that received WT cells showed a clear increase in TNP-specific antibody levels when compared with serum taken from the mice before immunization. An increase in TNP-specific antibodies could also be observed in UCOE.coRAG1-and SFFV.coRAG1-treated mice, showing the functional cooperation of B and T cells that were generated through gene therapy.
Selective advantage for cells with high RAG1 expression
To address the question whether the quantitative levels of RAG1 expression correlate with reconstitution, we related RAG1 expression levels in BM cells to the percentage of B cells in spleen for both B-cell-reconstituted and B-cell-negative mice (Figure 7a ). Based on these two parameters, a clear separation of B þ and BÀ mice could be seen, indicating a threshold level of RAG1 expression is needed to overcome the block in B-cell development. In addition, from total spleen cells we sorted B cells and myeloid cells in which we determined RAG1 expression levels relative to housekeeping gene ABL (Figure 7b ). Cells with high RAG1 expression levels were able to overcome the developmental block and migrate to periphery. Myeloid cells do not have this selective pressure for high RAG1 expression, reflected in low transgene expression levels found in the myeloid lineage in spleen. Together, this indicates that in Rag1À/À mice a selective advantage exists for lymphoid progenitor cells with high RAG1 expression. Despite the selective pressure, we did not observe oncogenic progression in any of the treated mice.
Discussion
In this report, we demonstrate the feasibility of SIN lentivirusbased correction of RAG-SCID in a preclinical model for this disease. The functional correction of the Rag1-deficient phenotype was achieved using lentiviral SIN vectors carrying a codonoptimized human RAG1 sequence, without the necessity of using high VCNs. In contrast, high VCNs were needed to reach a similar result with a LTR-driven g-retroviral vector in the preclinical Rag1À/À model of Lagresle-Peyrou et al., 17 which carries a high risk of insertional mutagenesis. 40, 41 For safety reasons, many laboratories have now focused on developing and testing alternative vectors for SCID. Foamy vector-mediated RAG1 gene transfer has so far also not succeeded in phenotypic correction at a low VCN (Dr DW Russell, personal communication). Likewise, using SIN lentiviral vectors without a codon-optimized transgene, it is still difficult to reach sufficient RAG1 expression when aiming for a low VCN (published by Lagresle-Peyrou et al. 29 and results shown here). As shown for other therapeutic genes, 30, 42, 43 optimizing the RAG1 sequence was important and beneficial for several reasons. First, we consistently achieve higher titers when producing coRAG1 viruses, suggesting that the RNA targeted for packaging was more stable for coRAG1 constructs in comparison with constructs carrying the native RAG1 sequence. Moreover, when cells transduced with a comparable multiplicity of infection of native or codon-optimized RAG1 vector, we find that transgene expression levels increase for both the absolute expression and the expression per vector copy. Indeed, the higher absolute level of transgene expression resulted in T-cell reconstitution in vivo, a result that could we could not obtain in experiments using SIN lentiviral vectors encoding native RAG1. Significantly, higher transgene expression levels and improved correction of the Rag1À/À phenotype were accomplished at low VCNs which is compatible with clinical translation. Comparing the native and codon-optimized vectors in vivo, the VCN found in BM 19 weeks after transduction is 3-to 13-fold higher in animals that received cells transduced with the native RAG1 vector. In contrast, the RAG1 expression in these SFFV.RAG1-treated mice was 2.5-fold lower than the SFFV.coRAG1-treated mice (the group showing both B-and T-cell reconstitution). On a per-copy basis, optimization resulted in an 18-fold higher transgene expression. Therefore, we conclude that codon optimization might be of critical importance to reach sufficient transgene expression, while refraining from high VCNs. In a separate experiment, we tested coRAG1 transduced cells were cultured in plates that were untreated or pre-coated with aCD3 and aCD28. After 3 days of culture, intracellular IL-2 and IFNg production was determined in CD4 þ and CD8 þ cells using flow cytometry. WT, n ¼ 5; RagÀ/À n ¼ 2 and SFFV.coRAG1, n ¼ 2. WT, *P-value ¼ 0.002 and SFFV. coRAG1, *P-value ¼ 0.0307. Statistical significance was determined by a two-tailed, unpaired t-test.
Preclinical lentiviral Rag1 gene therapy K Pike-Overzet et al the efficacy of a vector containing a ubiquitously acting chromatin opening element (A2UCOE), an element that is resistant to methylation-mediated silencing. 32 This UCOE.coR-AG1 vector resulted in an even higher transgene expression per integrated virus; comparing transgene expression per vector copy in BM, thymus and spleen cells, 20 weeks after transplantation, the UCOE.coRAG1 gave a 5-to 20-fold higher expression per integrated vector than SFFV.coRAG1. These properties allowed for correction of the Rag1À/À phenotype, while limiting the VCN. In that respect, the use of the UCOE.coRAG1 SIN lentiviral vector is promising for clinical application.
Besides the safety concerns in relation to provirus integration, persistent expression of RAG proteins could pose another safety risk. However, the in vivo gene therapy studies using g-retroviral transfer vectors expressing RAG as well as observations in Rag1 and Rag2 single-transgenic mice suggest that constitutively overexpressing one of the RAG proteins does not lead to malignancies or other pathological changes. We confirmed these observations in our current study. Only when both RAG1 and RAG2 proteins are ubiquitously expressed, do mice quickly develop lymphadenopathy, splenomegaly and lymphocytic perivascular infiltrates. 44 This is consistent with the fact that both RAG proteins are needed for recombinase activity and that biallelic mutations in only one of the RAG genes can lead to total lack of recombinase activity as observed in T-B-SCID patients as well as Rag1-and Rag2-deficient mice. 8, 31, 45 Considering these observations, it is unlikely that constitutive expression of either RAG1 or RAG2 would be harmful, as expression of the unaffected, endogenous RAG gene would regulate the activity of the RAG1/RAG2 complex. Figure 6 Reconstitution of B-cell function in mice that received gene therapy. (a) Twenty weeks after transplantation, IgM and IgG concentrations in the serum of mice that received WT, Rag1À/À, UCOE.coRAG1 or SFFV.coRAG1 LSK cells were determined by ELISA. WT, n ¼ 1; RagÀ/À, n ¼ 2, UCOE.coRAG1, n ¼ 3 and SFFV.coRAG1, n ¼ 3; *P ¼ 0.0026. Statistical significance was determined by a two-tailed, unpaired t-test. (b) At 13 and 15 weeks after transplantation, mice were challenged by intraperitoneal injection of TNP-KLH. Post-immunization serum (triangles) was tested for the presence of TNP-specific antibodies by ELISA using TNP-KLH coated plates. Pre-immunization serum (squares) was used as a negative control. Serial dilutions of the serum are plotted against the optical density at 415 nm of the sample after the ELISA procedure.
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Apart from achieving adequate levels of transgene expression, we found evidence for restoration of the recombinase activity mediated by the human/mouse hybrid RAG1/Rag2 protein complex. This activity could possibly improve in a completely human setting when the therapeutic RAG1 gene is paired with human RAG2. We were able to detect V(D)J rearrangements at the mRNA level as well as Ig and TCR on the cell surface of B and T cells, respectively. In addition, we detected the product of RAG-mediated rearrangement in the form of secreted Ig in the serum. Furthermore, we saw a robust complementation of the T-cell deficiency. Especially in SFFV.coRAG1, but also in UCOE.coRAG1-treated mice, the number of peripheral T cells approached WT numbers. T cells that developed in gene therapy-treated mice were also capable of proliferation and cytokine production upon stimulation of their TCR. In addition, when testing the function of T cells in vivo by way of intraperitoneal injections of TNP-KLH, we found antigenspecific antibodies in the serum. This indicates that the repertoire generated was sufficient to bring about an antigenspecific response. TNP-KLH elicits a T-cell-dependent B-cell response, so the presence of antigen-specific antibodies indicates proper cooperation of T and B cells. The fact that we were able to detect antibodies of the IgG isotype confirms this functional cross talk, as T cells are needed for the isotypeswitching process in B cells.
We recurrently observed reconstitution in the T-cell compartment, but measured low numbers of B cells. For SCID patients, there is an absolute clinical need to correct the T-cell deficiency, but a lack of B cells or a low number of B cells could be treated by administration of immunoglobulins and prophylaxis with antibiotics. Therefore, the robust T-cell reconstitution we observed is encouraging for clinical application, especially since gene therapy trials for SCID have shown sustained thymopoiesis up to 10.7 years after transplantation. 46 With respect to B-cell reconstitution, we found that in treated mice the overall numbers were rather low. Alternative conditioning regiments will have to be tested to improve B-lineage reconstitution. Interestingly, the lower percentage of B cells found in peripheral blood and spleen of gene therapytreated mice did not result in lower serum Ig levels as compared with WT animals. Apparently, a relatively low number of B lymphocytes is sufficient to reconstitute quantitative Ig production in this model.
In our study, a number of mice did not survive, most likely due to BM failure. This problem can be addressed further by optimizing the gene transfer procedure into true hematopoietic stem cells. Circumventing the relatively high toxicity of the vesicular stomatitis virus glycoprotein envelope, we could test the toxicity and gene transfer efficiency of lentiviral SIN vectors pseudotyped with RD114/TR. 47 Alternatively, we could aim for more specific targeting of hematopoietic stem cells by utilizing single-chain antibodies targeting the viral vector to CD133. 48 In addition, tailoring culture conditions to the expansion of hematopoietic stem cells should further improve reconstitution.
In this study, we have shown that the T-B-phenotype of Rag1À/À mice can be complemented using SIN lentiviral vectors to expressing codon-optimized RAG1. We observed selective advantage for lymphoid progenitor cells with high RAG1 expression and toxicity related to ectopic RAG1 expression was not observed. The vectors we tested were all devoid of GFP or other tags, a prerequisite for clinical application. Codon optimization is of critical importance to obtain sufficient RAG1 expression levels. In particular, when combining the chromatin opening element (A2UCOE) with the codon-optimized RAG1 sequence, adequate RAG1 expression levels were reached at the low VCN that is desired for gene therapy applications. In conclusion, fine-tuning the use of promoters or promoter-like elements in combination with the codon optimization of the RAG1 coding sequence has brought clinical application of lentivirus-based gene therapy for RAG1-SCID patients closer to reality. Yvette Caljouw in the mouse facility. We are grateful to L Naldini contributed vital new reagents; KPO, MR and FJTS analyzed data; KPO and FJTS interpreted data; YYN, AS, RCH, ACL, RGMB, GJAD, AJT, CB, MCC, JJMvD, AL and RH contributed in essential discussions. CL, SHBA and MCC contributed unpublished experiments that helped the direction of the work; KPO and FJTS wrote manuscript.
